Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
October 06, 2020 07:00 ET
|
Brickell Biotech, Inc.
Primary axillary hyperhidrosis is estimated to affect over 10 million people in the U.S. Sofpironium bromide is a retrometabolically designed investigational new chemical entity BOULDER,...
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
September 25, 2020 07:00 ET
|
Brickell Biotech, Inc.
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in...
Brickell Biotech to Participate in September Virtual Investor Conferences
September 10, 2020 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.
September 08, 2020 07:30 ET
|
Brickell Biotech, Inc.
IBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a...
Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
August 31, 2020 16:05 ET
|
Brickell Biotech, Inc.
Claims directed to novel crystalline forms of sofpironium bromide Patent protection in Japan granted through 2040 BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc....
Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020 16:01 ET
|
Brickell Biotech, Inc.
Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel...
Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
August 03, 2020 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering
June 17, 2020 22:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical
June 15, 2020 06:30 ET
|
Brickell Biotech, Inc.
Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis All primary and secondary endpoints were met and achieved statistical...
Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020 16:01 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., May 13, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...